|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2003-4-8
|
|
pubmed:abstractText |
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome that has been associated with the expression of platelet-derived growth factor b receptor (PDGFRbeta) fusion proteins, namely TEL/PDGFRbeta. These fusion proteins possess a constitutive PDGFRbeta tyrosine kinase activity, leading to aberrant PDGFRbeta signaling and cellular transformation. The expression of PDGFRbeta fusions in CMML could have therapeutic relevance, as PDGFRb is inhibited by the selective tyrosine kinase inhibitor, imatinib. Here, we investigated the possibility of employing imatinib to treat CMML.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
88
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
408-15
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12681968-Animals,
pubmed-meshheading:12681968-Cell Line, Transformed,
pubmed-meshheading:12681968-Cell Transformation, Neoplastic,
pubmed-meshheading:12681968-Humans,
pubmed-meshheading:12681968-Leukemia, Myelomonocytic, Chronic,
pubmed-meshheading:12681968-Mice,
pubmed-meshheading:12681968-Oncogene Proteins, Fusion,
pubmed-meshheading:12681968-Piperazines,
pubmed-meshheading:12681968-Pyrimidines,
pubmed-meshheading:12681968-Reverse Transcriptase Polymerase Chain Reaction
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia.
|
|
pubmed:affiliation |
Oncogenic Fusion Protein Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, 20133 Milan, Italy. rosalind.gunby@istitutotumori.mi.it
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
